ACA
SRPT icon

Atlas Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Atlas Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-100
Closed -$7.5K – 998
2022
Q2 		$7.5K Hold
100
– – ﹤0.01% 786
2022
Q1 		$7.81K Hold
100
– – ﹤0.01% 740
2021
Q4 		$9.01K Hold
100
– – ﹤0.01% 729
2021
Q3 		$9.25K Hold
100
– – ﹤0.01% 734
2021
Q2 		$7.77K Hold
100
– – ﹤0.01% 777
2021
Q1 		$7.45K Buy
+100
New +$9.23K ﹤0.01% 709

Other funds holding SRPT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Atlas Capital Advisors's SRPT Position: Q3 2022 in Review

Atlas Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2022, closing a stake of 100 shares — an estimated $7.5K sold.

Atlas Capital Advisors first reported a position in SRPT in Q1 2021 and held it in 6 quarters. The position peaked at $9.25K in Q3 2021. 375 funds tracked by Wall St. Rank hold SRPT as of Q3 2022.

  • Atlas Capital Advisors reported no remaining Sarepta Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Atlas Capital Advisors sold 100 Sarepta Therapeutics shares in Q3 2022, an estimated $7.5K.
  • Atlas Capital Advisors first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 6 quarters.
  • Atlas Capital Advisors's Sarepta Therapeutics position peaked at $9.25K in Q3 2021.
  • 375 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2022.

Based on Atlas Capital Advisors's 13F filing for Q3 2022, filed 8 Nov 2022.